C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology
+$0.08 today
- Market cap
- $325.01M
- Beta
- 2.93
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.82
Volume 2.75M
Average 2.76M
CCCC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
C4 Therapeutics, Inc.NASDAQ: CCCC
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.67M fell 51.5% year over year, behind the -43.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 33.3% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.
Context
- Stock-based compensation amounted to 53.1% of revenue in FY2025, down 30.2 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -51.5% toward the trailing-twelve-month pace of -43.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 19.1M USD
- Year-over-year change
- -35.6%
- 4-year CAGR
- -2.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.1M | -35.6% |
| FY2024 | 2024-12-31 | 29.66M | +8.9% |
| FY2023 | 2023-12-31 | 27.24M | -9.3% |
| FY2022 | 2022-12-31 | 30.02M | +39.5% |
| FY2021 | 2021-12-31 | 21.51M | — |
Stock-Based Compensation vs competitors
How CCCC compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -43.8% is the lowest of 9, against a peer median of -14.8%.
- Stock-based compensation amounts to 46.7% of revenue for CCCC, versus a peer median of 75.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.26M USD | -43.8% | -14.0% | 46.7% | |
| LTM Mar 2026 | $15.02M USD | -24.7% | -4.8% | 52.0% | |
| LTM Mar 2026 | $10.03M USD | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $8.67M USD | -29.5% | -12.8% | 11.1% | |
| LTM Mar 2026 | $7.48M USD | -39.0% | -34.0% | 21.6% | |
| LTM Mar 2026 | $6.14M USD | +9.4% | -6.2% | 344.3% | |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
| LTM Mar 2026 | $2.9M USD | -7.5% | -5.6% | 98.2% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.4M USD | +50.7% | -39.5% | 123.1% |
| Peer median (excluding CCCC) | — | -14.8% | -5.9% | 75.1% | |
Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.89M) | (128.18M) | (132.49M) | (105.32M) | (104.99M) |
| Depreciation & Amortization | 1.49M | 1.68M | 1.88M | 1.82M | 1.96M |
| Deferred Income Tax | 1.88M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 21.51M | 30.02M | 27.24M | 29.66M | 19.1M |
| Change in Working Capital | (30.09M) | (16.78M) | (6.94M) | 7.65M | (29.28M) |
| Accounts Receivables | (1.23M) | 4.24M | (10.33M) | 8.7M | 701K |
| Inventory | (2.63M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.18M) | (3.33M) | 273K | (119K) | (468K) |
| Other Working Capital | (25.05M) | (17.69M) | 3.12M | (930K) | (29.52M) |
| Other Non-Cash Items | 2.13M | 7.32M | 3.48M | 1.03M | 14.52M |
| Operating Cash Flow | (86.97M) | (105.94M) | (106.84M) | (65.16M) | (98.69M) |
| Capital Expenditures | (1.28M) | (5.5M) | (1.71M) | (180K) | (607K) |
| Acquisitions (Net) | 188.06M | (63.92M) | 0 | 0 | 0 |
| Purchases of Investments | (537.74M) | (219.53M) | (129.9M) | (284.32M) | (227.07M) |
| Sales of Investments | 349.68M | 283.45M | 289.96M | 233.23M | 219.08M |
| Other Investing Activities | (188.06M) | 63.92M | 0 | 0 | 0 |
| Investing Cash Flow | (189.34M) | 58.42M | 158.35M | (51.27M) | (8.6M) |
| Debt Repayment | 0 | 0 | (12.5M) | 0 | 0 |
| Common Stock Issued | 169.47M | 777K | 57.67M | 44.37M | 126.32M |
| Common Stock Repurchased | 0 | 0 | (110K) | (194K) | (193K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.94M | 370K | 426K | 1.16M | 274K |
| Financing Cash Flow | 171.4M | 1.15M | 45.49M | 45.34M | 126.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (104.9M) | (46.37M) | 97M | (71.09M) | 19.1M |
| Free Cash Flow | (88.24M) | (111.44M) | (108.55M) | (65.34M) | (99.3M) |
C4 Therapeutics, Inc.
NASDAQ:CCCC
Intrinsic Alpha fair value
Locked
Current Price
$2.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.